TLR7 agonist 20
TLR7 agonist 20 is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 0.22 μM. TLR7 agonist 20, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 can be used in studies related to non-inflammatory potent vaccine adjuvants.
For research use only. We do not sell to patients.
- CAS No.: 3029695-00-6
- Formula: C22H24N4O
- Molecular Weight:360.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
TLR7 0.22 μM (EC50) |
In Vitro
TLR7 agonist 20 (Compound 23) (≤ 10 μM) shows no cytotoxicity in the NCI60 human cancer cell line panel[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old)[1]
-
Dosage:10 μg (co-formulated with SARS-CoV-2 spike antigen); 10 μg (co-formulated with SARS-CoV-2 spike antigen and 50 μg alum)
-
Administration:i.m.; administered at week 0 and week 2
-
Result:Induced significantly higher anti-spike IgG2b (OD450 ≈ 0.9) and IgG2c (OD450 ≈ 0.8) levels compared to spike antigen alone.
Induced significantly higher anti-spike IgG (OD450 ≈ 2.5), IgG1 (OD450 ≈ 3.0), IgG2b (OD450 ≈ 0.7), and IgG2c (OD450 ≈ 0.8) levels compared to spike antigen alone when co-formulated with alum and spike antigen.
Chemical Information
-
CAS No. 3029695-00-6
-
Molecular Weight 360.45
-
Formula C22H24N4O
-
SMILES
CCCCC1=NC2=C(C3=CC=CC=C3N=C2N)N1CC4=CC=C(C=C4)CO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TLR7 agonist 20 Related Classifications
HY-158694 Related Classifications
Powered by Bioz